{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20","upperLimit":"45","value":"32"}]}],"title":"1-year PFS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"27","value":"16"}]}],"title":"2-year PFS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Determine the progression-free survival rate among all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg).\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.\n\nClofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Clofarabine"}],"paramType":"NUMBER","populationDescription":"all participants from phase I-II trial who are treated with any of the 4 dose levels of oral clofarabine","reportingStatus":"POSTED","timeFrame":"at 1 and 2 years","title":"All Phase I-II Participants: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}